A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
A Randomized, Parallel-Group Double-Blind, Biosimilar Trial to Compare Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of PB018 Versus Ocrevus® in Participants With Multiple Sclerosis (MS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Male or female participants diagnosed with RMS and PPMS forms of MS in accordance with the revised McDonald criteria
- Evidence of recent disease activity as defined in study protocol
- Neurological stability for ≥ 30 days before both screening and first study treatment
- Baseline EDSS score between 0 to 6.0 (both inclusive) for RMS patients and between 3.0 and 6.5 (both inclusive) for PPMS patients.
Key Exclusion Criteria:
- Patient diagnosed with RMS for more than 10 years duration with an EDSS score ≤2.0 at Screening
- Patients diagnosed with PPMS < 10 years with an EDSS at screening ≤ 5.0 or < 15 years with an EDSS at screening > 5
- Patient unable to complete or has a contraindication to an MRI
- Patient with contraindications and/or severe hypersensitivity to corticosteroids including methylprednisolone or any of the excipients of study drug or interventions defined in the study protocol.
- Patient who has currently or history of any of medical conditions described in the study protocol.
- Patients who have received or are going to receive any of prohibited medications or treatments defined in the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: US-Ocrevus
US-licensed Ocrevus(Ocrelizumab)
|
Intravenous(IV) infusion
|
|
Active Comparator: EU-Ocrevus
EU-approved Ocrevus(Ocrelizumab)
|
Intravenous(IV) infusion
|
|
Experimental: PB018
PB018 (Ocrelizumab)
|
Intravenous(IV) infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the concentration time curve
Time Frame: Week 0 to Week 24
|
Demonstrate similar PK between Ocrevus and PB018
|
Week 0 to Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to reach Maximum serum concentration (Cmax)
Time Frame: Week 0 and Week 2
|
Week 0 and Week 2
|
|
|
Area under the concentration time curve in participants treated with PB018 versus US-licensed Ocrevus
Time Frame: Week 0 to Week 16
|
Week 0 to Week 16
|
|
|
Area under the concentration time curve in participants treated with PB018 versus EU-approved Ocrevus
Time Frame: Week 0 to Week 16
|
Week 0 to Week 16
|
|
|
Tmax (W0)
Time Frame: Week 0
|
Week 0
|
|
|
Tmax (W2)
Time Frame: Week 2
|
Week 2
|
|
|
T1/2
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Clearance
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Elimination rate constant
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Volume of Distribution (Vz)
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Ctrough
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Mean residence time (MRT)
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
B-cell Depletion (CD19+ Cells)
Time Frame: Week 0 to Week 24
|
Assessment of pharmacodynamic similarity between PB018 and reference ocrelizumab products based on the proportion of participants with CD19+ B-cell counts below predefined thresholds.
|
Week 0 to Week 24
|
|
MRI Lesion Activity
Time Frame: Week 0; Week 12; Week 24
|
Assessment of similarity in MRI disease activity between PB018 and reference ocrelizumab products by evaluating new or enlarging brain lesions.
|
Week 0; Week 12; Week 24
|
|
Expanded Disability Status Scale (EDSS) score
Time Frame: Screening to Week 24
|
Use of Disability Status Scale to measure for disability progression.
|
Screening to Week 24
|
|
Total number of participants with positive anti-drug antibodies (ADAs)
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Total number of participants with neutralizing antibodies (Nab)
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Number of participants with treatment-emergent adverse events (TEAE) as assessed by CTCAE v6.0
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Number of participants discontinued due to adverse events / serious adverse events as assessed by CTCAE v6.0
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
|
|
Number of participants with treatment-emergent adverse events of special interest (TEAESI) as assessed by CTCAE v6.0
Time Frame: Week 0 to Week 24
|
Week 0 to Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PB018-01-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.